# Four Peptides, Four Very Different Regulatory Maps

> Compare Semaglutide, Thymosin Alpha-1, BPC-157 and MOTS-c — Peptide Asia — A side-by-side comparison of four research peptides — semaglutide, thymosin alpha-1, BPC-157 and MOTS-c — by regulatory status, evidence maturity and what each is actually studied for.

**COMPARE THE FOUR**

Same category of molecule, wildly different evidence bases — laid out side by side by approval status, trial maturity, and what each is actually studied for.

## The short version

It is tempting to treat 'peptide' as if it were a single category with a single standard of evidence behind it. It isn't. Of the four compounds on this desk, one is a fully approved prescription drug backed by trials of tens of thousands of people. One is approved as a medicine in dozens of countries but not the United States. Two are not approved anywhere and remain, formally, research chemicals — and even between those two, one has three small human pilot studies to its name and the other has none.

This page lines the four up directly: what each is studied for, how mature its human evidence is, and where it stands with regulators. None of this is a ranking of which peptide 'works better' — mechanisms, use cases and evidence maturity are different things, and conflating them is exactly the kind of shortcut this desk tries to avoid.

## Side by side

| | Semaglutide | Thymosin Alpha-1 | BPC-157 | MOTS-c |
|---|---|---|---|---|
| **Category** | GLP-1 receptor agonist | Thymic immunomodulatory peptide | Gastric-derived pentadecapeptide | Mitochondrial-derived peptide |
| **Primary research area** | Metabolic / weight | Immune function | Tissue repair | Metabolism / exercise / aging |
| **US regulatory status** | FDA-approved (multiple indications) [1][3][4] | Not FDA-approved; investigational/compounded only [7] | Not approved; research chemical only [14] | Not approved; research chemical only |
| **International status** | Approved in many jurisdictions alongside the US | Approved as thymalfasin in 35+ countries [7] | Not approved anywhere | Not approved anywhere |
| **Human trial scale** | Tens of thousands across multiple large outcome trials [1][2][3][4] | Over a thousand in the largest single trial [6]; decades of clinical-use data abroad [7] | Two human participants in the only dedicated safety pilot [13] | Zero interventional; one 94-person observational cohort [19] |
| **Strongest human evidence** | SELECT: reduced major cardiac events, HR 0.80, n=17,604 [3] | TESTS: no mortality benefit in sepsis despite the largest trial to date, n=1,106 [6] | IV safety pilot: well tolerated, no adverse events, n=2 [13] | Hemodialysis cohort: circulating levels associated with mortality/CV risk, n=94 [19] |
| **Dominant animal evidence** | Extensive rodent and mechanistic work underpins an already-approved drug | Rodent and in vitro dendritic-cell/T-cell work | Large rodent literature on angiogenesis and gastric repair [16][17] | Mouse studies on glucose handling, muscle preservation and exercise performance [18][21] |

## Reading the table honestly

A few things are worth naming plainly rather than leaving to the table alone.

**Approval status is not a proxy for how well something 'works.'** BPC-157 and MOTS-c being unapproved does not mean their mechanisms are implausible — the angiogenesis pathway behind BPC-157 [16] and the AMPK/CK2 pathway behind MOTS-c [18] are both mechanistically coherent and published in peer-reviewed journals. It means the *human* evidence has not yet reached the bar regulators require, which is a different and narrower claim.

**Being approved does not mean every question is settled.** Semaglutide's own head-to-head trial found it outperformed by a newer agent [1], and thymosin alpha-1's decades of approved use abroad did not predict the null result in its largest, best-designed sepsis trial [6]. Approval reflects an evidence bar being cleared for a specific indication, not a guarantee that every hoped-for use will pan out.

**The gap between BPC-157 and MOTS-c matters.** Both are unapproved research chemicals, but BPC-157 at least has three small human pilot studies behind it [14], while MOTS-c's only meaningful human data are an observational biomarker association, not an interventional study [19]. Treating the two as equally 'studied in humans' would flatten a real and important difference.

**Where a peptide sits regulatory-wise shapes what can be known about it.** Thymosin alpha-1's international approval enabled a 22-centre, 1,106-person trial [6] — a scale of coordination that is far harder to reach for a compound with no approved-drug status anywhere, which is a large part of why BPC-157 and MOTS-c remain stuck with thin or purely observational human data.

---

Peptide Asia draws its own map from published citations, not from borders or brochures — read it as a literature digest, never as a clinic, a shop, or a prescription.